Human Pathology
Volume 41, Issue 4 , Pages 485-492 , April 2010

Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder

  • Nafis Shafizadeh, MD

      Affiliations

    • Department of Pathology, University of California, San Francisco, CA 94121, USA
    • Drs. Shafizadeh and Grenert contributed equally to the manuscript.
    • ,
  • James P. Grenert, MD, PhD

      Affiliations

    • Department of Pathology, University of California, San Francisco, CA 94121, USA
    • Drs. Shafizadeh and Grenert contributed equally to the manuscript.
    • ,
  • Vaibhav Sahai, MD

      Affiliations

    • Department of Medicine, Mercy Hospital, Pittsburgh, PA 94143, USA
    • ,
  • Sanjay Kakar, MD

      Affiliations

    • Department of Pathology, University of California, San Francisco, CA 94121, USA
    • Veteran Affairs Medical Center, San Francisco, CA 94121, USA
    • Corresponding Author InformationCorresponding author. Department of Anatomic Pathology, UCSF and VA Medical Center, San Francisco, CA 94121.

Received 29 June 2009 ,Revised 29 September 2009 ,Accepted 1 October 2009.

References 

  1. Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg. 2008;207:594–603
  2. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009;208:134–147
  3. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125
  4. Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11:671–681
  5. Kelley ST, Bloomston M, et al. Cholangiocarcinoma: advocate an aggressive approach with adjuvant chemotherapy. Am Surg. 2004;70:743–748
  6. Takada T, Amano H, Yasuda H, et al. Is post-operative chemotherapy useful for gallbladder carcinoma? A phase III multi-center prospective randomized controlled trial in patients with resectable pancreatobiliary carcinoma. Cancer. 2002;95:1685–1695
  7. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122:985–993
  8. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20(18 Suppl):1S–13S
  9. Calvo E, Rowinsky EK. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr Oncol Rep. 2005;7:96–103
  10. Argyriou A, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumours. Mol Med. 2009;15:183–191
  11. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev. 2009;35:354–363
  12. Wiedmann M, Feisthammel J, Blüthner T, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs. 2006;17:783–795
  13. Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S. Gemcitabine in combination with EGFR antibody (cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer. 2006;6:190
  14. Paule B, Herelle MO, Rage E, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007;72:105–110
  15. Huang TW, Wang CH, Hsieh CB. Effects of the anti-epidermal growth factor receptor cetuximab on cholangiocarcinoma of the liver. Onkologie. 2007;30:129–131
  16. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24:3069–3074
  17. Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006;12:1680–1685
  18. Nonomura A, Ohta G, Nakanuma Y, et al. Simultaneous detection of epidermal growth factor receptor, epidermal growth factor, and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver. 1998;3:157–166
  19. Ito Y, Takeda T, Sasaki Y, et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract. 2001;197:95–100
  20. Altimari A, Fiorentino M, Gabusi E, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003;35:332–338
  21. Jan YY, Yeh TS, Yeh JN, et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg. 2004;240:89–94
  22. Kim HJ, Kim JS, Kang CD, et al. Expression of epidermal growth factor receptor, ErbB2, and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma. Korean J Gastro. 2005;45:52–59
  23. Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206:356–365
  24. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathologic and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418–425
  25. Kaufman M, Mehrotra B, Limaye S, et al. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci. 2008;5:285–291
  26. Ukita Y, Kato M, Terada T. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol. 2002;36:780–785
  27. Settakorn J, Kaewpila N, Burns GS, Leong S. FAT, e-cadherin, beta catenin, Her-2/neu, Ki-67 immunoexpression, and histologic grade in intrahepatic cholangiocarcinoma. J Clin Pathol. 2005;58:1249–1254
  28. Kim HJ, Yoo TW, Park DI, et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node positive patients. Ann Oncol. 2007;18:892–897
  29. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res. 2003;284:31–53
  30. Kari C, Chan TO, Rocha de Quadros M, et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 2003;63:1–5
  31. Marquez A, Wu R, Zhao J, et al. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol. 2004;13:1–8
  32. Kearsley JH, Leonard JH, Walsh MD, et al. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology. 1991;23:189–194
  33. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non–small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–3807
  34. Alvarez G, Perry A, Tan BR, et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Path. 2006;19:942–949
  35. Buckley AF, Burgart L, Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006;37:410–414
  36. Buckley AF, Burgart L, Kakar S. Epidermal growth factor receptor and gene copy number in conventional hepatocellular carcinoma. Am J Clin Path. 2008;129:245–251
  37. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9–S15
  38. Buckley AF, Kakar S. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol. 2007;15:305–309
  39. Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2001;130:22–28
  40. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist. 2002;7:31–39
  41. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803–1810
  42. Dei Tos AP, Ellis I. Assessing epidermal growth factor expression in tumors: what is the value of current test methods?. Eur J Cancer. 2005;41:1383–1392
  43. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–286
  44. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and Gefitinib sensitivity in non–small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–655
  45. Cappuzzo F, Ligorio C, Jänne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non–small-cell lung cancer: the ONCOBELL trial. J Clin Oncol. 2007;25:2248–2255
  46. Yoshikawa D, Ojima H, Kokubu A, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer. 2009;100:1257–1266
  47. Gwak GY, Yoon JH, Shin CM, et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol. 2005;131:649–652
  48. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. New England J Med. 2004;350:2129–2139
  49. Aishima SI, Taguchi KI, Sugimachi K, et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002;40:269–278
  50. Terada T, Ashida K, Endo K, et al. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology. 1998;33:325–331

PII: S0046-8177(09)00366-9

doi: 10.1016/j.humpath.2009.10.002

Human Pathology
Volume 41, Issue 4 , Pages 485-492 , April 2010

Article Tools

* Image Usage & Resolution